


NT-proCNP ELISA



NT-proCNP correlates with growth velocity

For clinical and preclinical samples


CE marked

Setting the **standard**
for **clinical** research.



Features and Benefits

- RELIABLE and FULLY VALIDATED – according to ICH Q2
- LOW SAMPLE VOLUME – only 20 µl of sample required
- SERUM-BASED STANDARDS and CONTROLS INCLUDED – for biologically reliable data
- CE MARKED – for IVD use in the EU



NT-proCNP is secreted by the growth plate and **levels reflect the rate of long bone growth** of the immature skeleton.

Plasma C-Type Natriuretic Peptide: Emerging Applications in Disorders of Skeletal Growth.

Espiner E, et al. Horm Res Paediatr. 2019.

NT-proCNP is a potential **early biomarker of recombinant human growth hormone efficacy**.

Dynamic response of C-type natriuretic peptide and its aminoterminal propeptide (NTproCNP) to growth hormone treatment in children with short stature.

Olney RC, et al. Clin Endocrinol (Oxf). 2016.

Measurement of amino-terminal propeptide of C-type natriuretic peptide in patients with idiopathic short stature or isolated growth hormone deficiency.

Xiao Y, et al. J Pediatr Endocrinol Metab. 2011.

Assay Characteristics

- Method: Sandwich ELISA, HRP/TMB, 12x8-well strips
- Sample type: Plasma (EDTA, heparin, citrate), serum, urine, cell culture supernatant
- Sample volume: 20 µl / test
- Assay time: < 4 h
- Sensitivity: 0.7 pmol/l (= 3.49 pg/ml)
- Standard range: 0 - 128 pmol/l (7 standards and 2 controls in a human serum matrix included)
- Specificity: Endogenous and recombinant human and non-human NT-proCNP
- Precision: Within-run (n=5): ≤ 6% CV; In-between-run (n=8): ≤ 7% CV

More information and full validation report are available at www.bmgrp.com

Related Biomedica Products

- FGF23 (intact) human ELISA, Cat.No. BI-20700
- FGF23 (C-terminal) multi-matrix ELISA, Cat.No. BI-20702